Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. (5th June 2018)

• Record Type: Journal Article
• Authors: Fernandez, Agustin F; Bayón, Gustavo F; Sierra, Marta I; Urdinguio, Rocio G; Toraño, Estela G; García, Maria G; Carella, Antonella; López, Virginia; Santamarina, Pablo; Pérez, Raúl F; Belmonte, Thalía; Tejedor, Juan Ramon; Cobo, Isabel; Menendez, Pablo; Mangas, Cristina; Ferrero, Cecilia; Rodrigo, Luis; Astudillo, Aurora; Ortea, Ignacio; Cueto Díaz, Sergio; Rodríguez-Gonzalez, Pablo; García Alonso, J Ignacio; Mollejo, Manuela; Meléndez, Bárbara; Domínguez, Gemma; Bonilla, Felix; Fraga, Mario F
• Is Part Of: Human molecular genetics. Volume 27:Number 17(2018:Sep. 01)
• Page Start: 3046
• Page End: 3059
• Publication Date: 2018-06-05
• Subjects: Human molecular genetics -- Periodicals; Human chromosome abnormalities -- Periodicals; 572.8
• DOI: 10.1093/hmg/ddy214
• Languages: English
• ISSNs: 0964-6906

Abstract

Abstract: Aberrant DNA hypermethylation is a hallmark of cancer although the underlying molecular mechanisms are still poorly understood. To study the possible role of 5-hydroxymethylcytosine (5hmC) in this process we analyzed the global and locus-specific genome-wide levels of 5hmC and 5-methylcytosine (5mC) in human primary samples from 12 non-tumoral brains and 53 gliomas. We found that the levels of 5hmC identified in non-tumoral samples were significantly reduced in gliomas. Strikingly, hypo-hydroxymethylation at 4627 (9.3%) CpG sites was associated with aberrant DNA hypermethylation and was strongly enriched in CpG island shores. The DNA regions containing these CpG sites were enriched in H3K4me2 and presented a different genuine chromatin signature to that characteristic of the genes classically aberrantly hypermethylated in cancer. As this 5mC gain is inversely correlated with loss of 5hmC and has not been identified with classical sodium bisulfite-based technologies, we conclude that our data identifies a novel 5hmC-dependent type of aberrant DNA hypermethylation in glioma.